Jason Vickress1, Michael Lock1,2,3, Simon Lo4, Stewart Gaede1,2,3, Aaron Leung2, Jeff Cao2,3, Rob Barnett1,2,3, Slav Yartsev1,2,3. 1. Department of Medical Biophysics, Western University, London, ON, Canada. 2. Department of Oncology, Western University, London, ON, Canada. 3. London Regional Cancer Program, London Health Sciences Centre, London, ON, Canada. 4. Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Abstract
AIM: New parameters that correlate with overall survival were identified in patients with liver lesions treated with radiation therapy. METHODS: Pretreatment information and parameters of radiation treatment plans for 129 metastatic and 66 hepatocellular carcinoma liver cancer patients were analyzed. Study end points included overall survival collected from patient charts and electronic records. RESULTS: Two practical nomograms were constructed for primary hepatocellular carcinoma and liver metastasis patients. For patients with a Child-Pugh A, radiation dose escalation provided a significant survival benefit. However, for those with Child-Pugh B or C, increasing dose does not impact on survival. CONCLUSION: The developed models can potentially guide dose selection and provide prognostic information but still require external validation.
AIM: New parameters that correlate with overall survival were identified in patients with liver lesions treated with radiation therapy. METHODS: Pretreatment information and parameters of radiation treatment plans for 129 metastatic and 66 hepatocellular carcinoma liver cancerpatients were analyzed. Study end points included overall survival collected from patient charts and electronic records. RESULTS: Two practical nomograms were constructed for primary hepatocellular carcinoma and liver metastasispatients. For patients with a Child-Pugh A, radiation dose escalation provided a significant survival benefit. However, for those with Child-Pugh B or C, increasing dose does not impact on survival. CONCLUSION: The developed models can potentially guide dose selection and provide prognostic information but still require external validation.
Authors: Stephanie K Schaub; Pehr E Hartvigson; Michael I Lock; Morten Høyer; Thomas B Brunner; Higinia R Cardenes; Laura A Dawson; Edward Y Kim; Nina A Mayr; Simon S Lo; Smith Apisarnthanarax Journal: Technol Cancer Res Treat Date: 2018-01-01